Lifers with Christina Farr

In this episode of Lifers, Chrissy sits down with longtime friend Adam Pellegrini, the CEO of TytoCare, who has seen healthcare from just about every side: Army medic, Microsoft, Walgreens, Fitbit, CVS Health, and startups like Jasper and Kaia Health. Adam unpacks what he’s learned moving between insurgents and incumbents, why TytoCare’s urgent care partners are seeing NPS scores of 92, and why the future of remote patient monitoring is health systems and plans building it into the standard of care themselves. Along the way: the remote patient monitoring graveyard, the prescription “pizza tracker” he built at Walgreens, his visit to Theranos, selling Kaia to Sword without a banker, why ten-year VC timelines clash with a 20-year industry, why selling to employers is so tough, and why simple ideas often beat big ones. — SPONSOR: TytoCare is transforming how healthcare is delivered beyond the clinic with an AI Care Enablement Platform that helps health systems and health plans provide more accessible, proactive, and continuous care. Combining FDA-cleared remote physical exams, connected devices, clinical AI, patient engagement, and clinician workflows, TytoCare enables care teams to assess patients remotely, identify meaningful changes in their health earlier, and intervene before conditions escalate. From urgent care and virtual visits to longitudinal management of chronic and complex conditions like COPD, TytoCare helps healthcare organizations expand access, improve outcomes, and reduce the cost of care. — Lifers is brought to you by: Hippocratic AI Hippocratic AI builds safety-focused voice AI agents that call the patients health systems don’t have the staff to reach, with more than 250 million patient interactions to date. Learn more at hippocraticai.com. Learn more at hippocraticai.com and watch the Lifers episode with Hippocratic AI CEO Munjal Shah: https://www.youtube.com/watch?v=fUACDfWRddM – LINKS: TytoCare: https://www.tytocare.com/ Chrissy Farr on YouTube: ⁠⁠https://www.youtube.com/@LiferswithChristinaFarr⁠⁠ Chrissy Farr on Instagram: ⁠⁠https://www.instagram.com/cfarr/⁠⁠ Subscribe to the Second Opinion Newsletter: ⁠⁠https://secondopinion.media/⁠⁠ Chrissy’s Book: The Storyteller's Advantage: ⁠⁠https://www.chrissyfarr.com/books⁠⁠ — FOLLOW: TytoCare: https://www.linkedin.com/company/tyto-care-ltd-/ Adam Pellegrini: https://www.linkedin.com/in/adampellegrini/ Chrissy:⁠⁠ https://www.linkedin.com/in/christinafarr/⁠⁠ ⁠⁠https://x.com/chrissyfarr⁠⁠ Second Opinion Media: ⁠⁠⁠⁠https://www.instagram.com/second.opinion.media/⁠⁠ ⁠⁠https://x.com/second_op_media⁠⁠ — TIMESTAMPS: (0:00) Intro (1:12) Welcome Adam Pellegrini (3:19) From Army medic to Microsoft, Walgreens, and Fitbit (8:22) CVS Health and telemedicine through Covid (11:08) Jasper, Kaia, and selling to Sword (15:26) Insurgents vs. incumbents (20:18) Joining TytoCare (21:43) A 92 NPS? (25:50) The remote patient monitoring graveyard (28:29) Why health systems are insourcing (30:36) Big ideas vs. small ideas (33:14) The prescription pizza tracker and Theranos (39:47) Can VC timelines work in healthcare? (46:01) Who should healthcare startups sell to? (56:29) Cutting out the middlemen

In this episode of Lifers, filmed live at the Second Opinion Summit, two surgeons take on health care’s version of Minority Report: can AI predict a patient’s future? Dr. Jay Shah, Chief Medical Officer of Concurrence and a Stanford cancer surgeon, and Dr. Prakash Jayakumar, Senior Medical Director at Optum Insight and an orthopedic surgeon, dig into what a digital twin really is, why the medical record is “an imperfect, stochastic map of a deeply complex human life,” and why the data that matters most lives in the 99.9% of a patient’s life that happens between appointments. Along the way: why 20 to 25% of knee replacement patients are unhappy, what ambient scribes leave out, Jay’s brush with septic shock, the surgical M&M as health care’s closest thing to a learning system, and the 82-year-old patient whose “wrong” treatment choice was the right one. — SPONSOR: Concurrence, formerly Amigo, builds clinical AI agents that care for patients between visits. The agents handle outreach, intake and triage, follow-up and medication support. Before an agent talks to a real patient, it’s trained like a doctor through Concurrence’s “Digital Residency” on millions of simulated patient interactions. Dr. Jay Shah, Concurrence’s Chief Medical Officer and Chief of Medical Staff at Stanford Health Care, sat down with Dr. Prakash Jayakumar, orthopedic surgeon and value-based care leader, to talk about what AI can and can’t see about a patient, from ambient scribes to digital twins. — LINKS:  Concurrence: https://www.concurrence.com/ Chrissy Farr on YouTube: ⁠https://www.youtube.com/@LiferswithChristinaFarr⁠  Chrissy Farr on Instagram: ⁠https://www.instagram.com/cfarr/⁠  Subscribe to the Second Opinion Newsletter: ⁠https://secondopinion.media/⁠  Chrissy’s Book: The Storyteller's Advantage: ⁠https://www.chrissyfarr.com/books⁠  — FOLLOW: Chrissy: ⁠https://www.linkedin.com/in/christinafarr/⁠  ⁠https://x.com/chrissyfarr⁠  Second Opinion Media:⁠ https://www.instagram.com/second.opinion.media/⁠  ⁠https://x.com/second_op_media⁠  Concurrence: https://www.linkedin.com/company/concurrencehq/ — TIMESTAMPS: (0:00) Intro (0:42) Live from the Second Opinion Summit at the White Hotel (1:10) Health care’s Minority Report: can we predict disease? (2:21) Meet Dr. Jay Shah and Dr. Prakash Jayakumar (4:06) Jay: being sick is a full-time job with no pay (5:25) Jay’s near-death experience with septic shock (6:56) Prakash: from orthopedic surgeon to systems thinker (10:20) Don’t doctors already predict the future? (14:07) Why 20–25% of knee replacement patients are unhappy (17:51) What is a digital twin, really? (19:53) Digital twin vs. a PubMed study (20:57) The other 99.9% of a patient’s life (24:15) What ambient scribes leave out (27:20) The medical record isn’t the source of truth (28:03) Privacy and the lessons of social media (30:30) The three eras: data, prediction, decision intelligence (31:25) “Are you the one in charge of my care?” (35:00) Sharing more data and the learning loop (36:57) Why patients never see their own outcome data (38:00) Learning health systems and the M&M conference (41:03) Will AI replace doctors? (43:30) The 82-year-old patient: when the “wrong” answer is right (46:58) What comes next for AI prediction (48:20) Wrap

Dr. Ilya Burkov, Global Head of Scientific AI and Healthcare at Nebius, and Thomas Knox, Co-founder and CEO of VitVio, join Christina Farr to talk about why AI companies are crowding into healthcare and what it takes to actually get adopted. Thomas explains how VitVio’s ambient sensing in the operating room can hear a drill before it fails, and why he thinks decades of consolidation and early acquisitions have kept healthcare a step behind. Ilya makes the case that healthcare is AI’s best-case argument, not its scariest, and that what made AI scribes finally take off was the infrastructure underneath them. —Thanks to Nebius who facilitated this conversation. Nebius, the AI cloud company, is building the full-stack platform for developers and companies to take charge of their AI future — from data and model training to production deployment. Founded on deep in-house technological expertise and operating at scale with a rapidly expanding global footprint, Nebius serves startups and enterprises building AI products, agents, and services worldwide. Nebius is listed on Nasdaq (Nasdaq: NBIS) and headquartered in Amsterdam. —Lifers is brought to you by: Hippocratic AIHippocratic AI builds safety-focused voice AI agents that call the patients health systems don’t have the staff to reach, with more than 250 million patient interactions to date. Learn more at hippocraticai.com. Learn more at hippocraticai.com and watch the Lifers episode with Hippocratic AI CEO Munjal Shah: https://www.youtube.com/watch?v=fUACDfWRddM  —Join Christina for upcoming webinars:• 10/28 - Type 2 Diabetes & Cardiometabolic Care: Wearables, AI & GLP-1s https://streamyard.com/watch/uAuwCzUEJTCF • 11/3 - Is It Finally the Moment for Alternative Plan Design? https://streamyard.com/watch/ereM3aB58XK4  —LINKS: Nebius, Life Sciences & Healthcare: https://nebius.com/solutions/life-sciences-and-healthcare VitVio: https://www.vitvio.com Nebius AI Discovery Awards (VitVio placed 2nd in Digital Health): https://nebius.com/newsroom/nebius-celebrates-healthcare-and-life-sciences-innovators-at-expanded-ai-discovery-awards CommonSpirit on transitioning off Conifer’s revenue cycle services: https://www.commonspirit.org/news-articles/commonspirit-to-transition-conifer-revenue-cycle-services Chrissy Farr on YouTube: https://www.youtube.com/@LiferswithChristinaFarr Chrissy Farr on Instagram: https://www.instagram.com/cfarr/ Subscribe to the Second Opinion Newsletter: https://secondopinion.media/ Chrissy’s Book: The Storyteller's Advantage: https://www.chrissyfarr.com/books  —FOLLOW:Ilya:https://www.linkedin.com/in/ilyaburkov/ https://x.com/ilyaburkov  Thomas:https://www.linkedin.com/in/thomas-knox/  Chrissy:https://www.linkedin.com/in/christinafarr/ https://x.com/chrissyfarr  Second Opinion Media:https://www.instagram.com/second.opinion.media/ https://x.com/second_op_media —TIMESTAMPS:(00:00) Lead in(01:03) Meet Dr. Ilya Burkov and Thomas Knox(02:27) AI momentum in hospitals(04:11) VitVio OR vision(05:50) Founder origin story(08:15) Capturing OR context(09:19) Safety guardrails for AI(11:03) Predictive OR automation(14:40) Prevention and biomarkers(16:47) Incentives shape AI(18:57) Efficiency and trust(25:27) Clinician-led adoption(33:29) Infrastructure enables scale(35:47) Hospital leverage and contracts(37:29) Consolidation vs competition(47:33) Committees and market noise(54:02) AI becomes invisible(55:38) Wrap

In Episode 6 of Rounds: The Mental Health Moment, Christina Farr and Stephanie Davis break down the latest healthcare headlines, then dig into the mental health space with Jake Cooper, CEO and Co-Founder of Grow Therapy, and Jon Cohen, CEO of Talkspace. We'll cover: The latest headlines: CommonSpirit exiting its Conifer contract for $1.9B, Waystar exploring options including a sale, the rally in AI drug discovery names, and Neuberger and KKR investing in Datavant alongside New Mountain Capital How Grow Therapy differentiated from incumbents, what's next after its $150M Series D at a $3B valuation, and how it scales to 27,000+ providers without losing quality and continuity of care Where AI belongs in mental health care, from cutting provider documentation time by ~70% to the clinical relationship itself Why 73% of adults who knew they needed care skipped it, and why traditional EAPs leave employers needing a connected path instead of a cliff Talkspace's road from SPAC to UHS subsidiary, including the pivot from a D2C subscription app to a payor-based, in-network model What day one inside a hospital system looks like, and what the UHS deal signals about consolidation vs. staying independent Timestamps: (0:00) Intro (0:41) Conifer layoffs and the insourcing trend (3:10) Waystar explores a sale (5:42) AI drug discovery stocks rally (7:47) Datavant investment (9:35) Healthcare is investors' top underweight (12:28) Jake Cooper, CEO of Grow Therapy (16:03) Why Jake started Grow (19:25) Growth vs. profitability (21:41) Staying independent (23:36) The employer market and Amazon (26:55) Jon Cohen, CEO of Talkspace (29:17) Consolidation in healthcare (29:55) Inside the UHS deal (32:49) 1099 vs. W2 therapists (36:10) 100M people a week talk to AI about mental health (37:43) How Talkspace got acquired (39:46) Bonus: AI and mental health with both CEOs (41:58) How do we regulate mental health AI? (48:05) Who pays for it? (49:58) Text or voice? (51:12) Will AI make therapists busier? (54:16) Wrap-up Hosts and Guests: Christina Farr, CEO, Second Opinion; GP, Scrub Capital Stephanie Davis, Healthcare Industry Analyst Jake Cooper, CEO and Co-Founder of Grow Therapy Jon Cohen, CEO of Talkspace Sponsored by Silicon Valley Bank.

Christina Farr talks with David Benshoof Klein, Founder and CEO of Click Therapeutics, days after the FDA cleared Motivista, the first authorized treatment for the negative symptoms of schizophrenia. They discuss why so many digital therapeutics companies failed, and why an FDA-authorized app still has to fight for the coverage a drug would get automatically. David also explains why he thinks AI tools, not pharma sales reps, may be what puts treatments like Motivista in front of doctors.—SPONSOR:Click Therapeutics builds medical-grade patient software across digital therapeutics, software-enhanced drugs, wellness & wearables, and AI-enabled interventions. Its platform offers a library of 100+ validated modules backed by rigorous clinical testing, bringing biotech rigor to any condition with a neurological or behavioral component.To learn more about Click: https://www.clicktherapeutics.com/ To learn more about Motivista: https://www.motivista.com/—Join Christina for upcoming webinars:10/13 - Verifying AI in Medicine: Is Healthcare AI Actually Ready for Deployment? https://streamyard.com/watch/GwsSXwdikhMw 10/28 - Type 2 Diabetes & Cardiometabolic Care: Wearables, AI & GLP-1s https://streamyard.com/watch/uAuwCzUEJTCF 11/3 - Is It Finally the Moment for Alternative Plan Design? https://streamyard.com/watch/ereM3aB58XK4 —LINKS:FDA clears Motivista (CT-155): https://www.clicktherapeutics.com/news/fda-clears-motivista-ct-155-the-first-therapeutic-indicated-for-the-treatment-of-the-negative-symptoms-of-schizophrenia CT-132, Click’s episodic migraine program: https://www.clicktherapeutics.com/products/ct-132 FDA draft guidance, Regulatory Considerations for Prescription Drug Use-Related Software (PDURS): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-prescript ion-drug-use-related-software Click acquires Better Therapeutics’ assets, 2024: https://www.businesswire.com/news/home/20240522194752/en/Click-Therapeutics-Accelerates-Expansion-into-Obesity-and-Cardiometabolic-Disease-With-Acquisition-of-the-Assets-of-Better-Therapeutics-Inc  Chrissy Farr on YouTube: https://www.youtube.com/@LiferswithChristinaFarr Chrissy Farr on Instagram: https://www.instagram.com/cfarr/ Subscribe to the Second Opinion Newsletter: https://secondopinion.media/ Chrissy’s Book: The Storyteller's Advantage: https://www.chrissyfarr.com/books  —FOLLOW:David:https://www.linkedin.com/in/davidbklein/ Chrissy:https://www.linkedin.com/in/christinafarr/ https://x.com/chrissyfarr Second Opinion Media:https://www.instagram.com/second.opinion.media/ https://x.com/second_op_media —TIMESTAMPS:(00:00) Lead in(00:30) Intro(01:46) First for schizophrenia(02:20) What digital therapeutics means(04:01) Software treats disease(05:35) Drugs plus software(06:55) Negative symptoms explained(09:56) Designing adaptive goals(13:50) Safety and autonomy(16:03) Generative AI in care(22:48) Regulation and evidence(26:55) Digital therapeutics graveyard(27:51) Digital therapeutics graveyard(28:40) Why programs fail evidence(29:38) Click survival playbook(30:50) Commercialization and coverage(31:46) Pharma launch gap(33:42) AI driven prescribing wave(36:37) FDA guidance and pharma cycles(40:56) Pricing value and access(43:48) Hiring for scrappy commercial(46:38) Future of venture and consumers(51:31) OTC migraine and AI assistants(53:42) Text messaging engagement engine(55:15) Wrap